Multifunctional receptor-targeting antibodies for cancer therapy.
Multifunctional receptor-targeting antibodies for cancer therapy.
复制标题
DOI：
10.1016/s1470-2045(15)00039-x
复制
发表时间：
2015-11
期刊：
影响因子：
--
通讯作者：
Yanni Zhu;Sung Hugh Choi;K. Shah
中科院分区：
文献类型：
--
作者：
Yanni Zhu;Sung Hugh Choi;K. Shah
在过去的十年中，靶向不同肿瘤类型细胞表面受体的单特异性抗体已经取得了巨大的成功，并一直处于癌症治疗的最前沿。然而，肿瘤细胞内不同途径之间以及肿瘤细胞与其微环境之间的冗余信号传导和串扰可能限制基于受体靶向单特异性疗法的功效。抗体工程技术的进步使得同时靶向多种受体的策略能够规避常规单特异性疗法的限制并实现增强的治疗功效。在过去的5年中，出现了一系列多功能、受体靶向、基于抗体的分子，其允许靶向肿瘤微环境中的肿瘤细胞和内皮细胞或免疫细胞上的多个表面受体。在这篇综述中，我们讨论了使用多功能受体靶向抗体的原理和策略，它们的作用机制，以及它们作为癌症治疗剂的前景和挑战。这些知识为改善癌症患者当前的靶向治疗结果提供了机会。
During the past decade, monospecific antibodies targeting cell-surface receptors in different tumour types have achieved substantial success and have been at the forefront of cancer treatment. However, redundant signalling and crosstalk between different pathways within tumour cells and between tumour cells and their microenvironment can limit the efficacy of receptor-targeted monospecific-based therapies. Advances in antibody engineering technologies have enabled strategies that simultaneously target multiple receptors to circumvent the limitations of conventional monospecific therapies and achieve enhanced therapeutic efficacy. In the past 5 years, a range of multifunctional, receptor-targeting, antibody-based molecules have emerged, which allow targeting of multiple surface receptors on tumour cells and endothelial or immune cells in the tumour microenvironment. In this Review, we discuss the rationales and strategies for the use of multifunctional receptor-targeting antibodies, their mechanisms of action, and the promises and challenges they hold as cancer therapeutics. This knowledge provides opportunities to improve current targeted therapy outcomes for patients with cancer.